Clinical trials have revealed that patients with EGFR-mutated NSCLC who received EGFR TKIs such as erlotinib and afatinib experienced improvements in tissue progression when compared to chemotherapy [94, 95]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.